主页 > 医学动态 >
【技术产业】赛诺菲收购Oxford BioMedica
By Salamander Davoudi
Published: February 12 2008 02:00 | Last updated: February 12 2008 02:00
Oxford BioMedica shares jumped 27 per cent on Monday on the back of speculation that the UK biotechnology company is about to be bought by Sanofi Aventis, its French partner.
Analysts believe any offer for the company would be about the 50p level, valuing the business at about £280m ($547m).
This is less than the EU 518m ($,753m, £385m) Sanofi could have to pay the biotech company under the terms of a licensing deal for TroVax, a cancer vaccine being developed for renal, prostate and colorectal cancer.
Navid Malik, an analyst at Collins Stewart, said: “Sanofi Aventis has committed about £350m and if everything is successful they are never going to pay this when the company is so cheap at the moment.”
Oxford BioMedica’s shares have fallen more than 60 per cent in the past six months. Analysts believe Sanofi could be waiting for a final safety review for TroVax, due in the next few months.
Paul Cuddon, an analyst at KBC Peel Hunt, said: “There may have to be a data trigger, they may be waiting for the final TroVax safety review before they do a deal and this is coming fairly soon.”
Oxford BioMedica is also expecting Phase I/II data for ProSavin, its gene-based therapy for Parkinson’s disease this year. Phase III data for Trovax will not be known until 2009.
A deal between the two companies has long been expected. Sanofi’s cancer products are ageing. Acomplia, its new obesity treatment, has huge potential but has been delayed by regulators, while Plavix, its blood thinner, faces competition.
During the past 12 months the UK biotechnology sector has suffered from plunging share prices and increasing investor scepticism as drugs have been slow to develop.
Shares in Oxford BioMedica rose 5p to 23¾p.
Sanofi and Oxford BioMedica declined to comment. 本人认领此文翻译，若48小时后仍未提交译文，则由其他战友自由认领。 Takeover rumours revitalise Oxford BioMedica
收购传闻振兴牛津生物
Oxford BioMedica shares jumped 27 per cent on Monday on the back of speculation that the UK biotechnology company is about to be bought by Sanofi Aventis, its French partner.
基于牛津生物科技公司将被它的法国股东赛诺菲-安万特公司收购的传闻，该公司的股票上周一上涨了百分之二十七。
Analysts believe any offer for the company would be about the 50p level, valuing the business at about £280m ($547m).
分析家相信收购的股票价格将不会低于50英镑水平，估计整个交易将价值2.8亿英镑（5.47亿美元）。
This is less than the EU 518m ($,753m, £385m) Sanofi could have to pay the biotech company under the terms of a licensing deal for TroVax, a cancer vaccine being developed for renal, prostate and colorectal cancer.
这将比赛诺菲根据合同条款购买trovax的授权的价格便宜 ，该费用为5.18亿欧元（7.53亿美元或3.85亿英镑）。TroVax一个正在研制的针对肾癌，前列腺癌和大肠癌的癌症疫苗。
Navid Malik, an analyst at Collins Stewart, said: “Sanofi Aventis has committed about £350m and if everything is successful they are never going to pay this when the company is so cheap at the moment.”
Navid Malik，Collins Stewart公司的分析师，他说：“赛诺菲安万特公司已经承诺支付3.5亿英镑，事情顺利的话，他们将不必支付这么多，牛津生物的股票价格目前是如此的低”。
Oxford BioMedica’s shares have fallen more than 60 per cent in the past six months. Analysts believe Sanofi could be waiting for a final safety review for TroVax, due in the next few months.
牛津生物公司的股票在过去的六个月中下跌了60%。分析家相信赛诺菲在等待关于TroVax的最终安全评估，该评估将在近几个月公布。
Paul Cuddon, an analyst at KBC Peel Hunt, said: “There may have to be a data trigger, they may be waiting for the final TroVax safety review before they do a deal and this is coming fairly soon.”
Paul Cuddon, KBC Peel Hunt公司的分析家说：“应该有一些数据作为触发这笔买卖的契机，做这笔生意之前，他们应该在等待关于TroVax最终的安全评估，这是很快的事了。”
Oxford BioMedica is also expecting Phase I/II data for ProSavin, its gene-based therapy for Parkinson’s disease this year. Phase III data for Trovax will not be known until 2009.
Oxford BioMedica公司还希望得到关于 ProSavin的I/II期临床试验数据，今年开发的一种基于基因的治疗帕金森病药物。关于Phase 的III期临床数据结果直到2009年才能得出。
A deal between the two companies has long been expected. Sanofi’s cancer products are ageing. Acomplia, its new obesity treatment, has huge potential but has been delayed by regulators, while Plavix, its blood thinner, faces competition.
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-03-15 05:14
医学,生命科学网